Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MT203 in Healthy Japanese and Caucasian Males
NCT02354599Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2014
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of namilumab in rheumatoid arthritis (RA) and plaque psoriasis (8 cohorts), sponsored by Takeda. Primary endpoint: Treatment-emergent Adverse Events at Day 85. Started Nov 2014; status: completed.
02
Drugs
namilumab
03
Conditions
rheumatoid arthritis (RA)plaque psoriasis
Beyond the preview
Go deeper on NCT02354599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354599.